{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:31:26Z","timestamp":1791923486695,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40262-024-01437-5","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T09:23:45Z","timestamp":1730971425000},"page":"1529-1546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Drug\u2013Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir and Maribavir: Guidance for Clinicians"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7279-2818","authenticated-orcid":false,"given":"David M.","family":"Burger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Nijboer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Ghobreyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Blijlevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luuk","family":"Hilbrands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije C.","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Ljungman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-725X","authenticated-orcid":false,"given":"Roger J. M.","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"issue":"1","key":"1437_CR1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/cid\/ciaa1713","volume":"73","author":"HN Imlay","year":"2021","unstructured":"Imlay HN, Kaul DR. Letermovir and maribavir for the treatment and prevention of cytomegalovirus infection in solid organ and stem cell transplant recipients. Clin Infect Dis. 2021;73(1):156\u201360.","journal-title":"Clin Infect Dis"},{"issue":"25","key":"1437_CR2","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"1437_CR3","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","volume":"75","author":"RK Avery","year":"2022","unstructured":"Avery RK, Alain S, Alexander BD, Blumberg EA, Chemaly RF, Cordonnier C, et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin Infect Dis. 2022;75(4):690\u2013701.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1437_CR4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2023.9106","volume":"330","author":"AP Limaye","year":"2023","unstructured":"Limaye AP, Budde K, Humar A, Vincenti F, Kuypers DRJ, Carroll RP, et al. Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial. JAMA. 2023;330(1):33\u201342.","journal-title":"JAMA"},{"key":"1437_CR5","unstructured":"Food & Drug Administration. Prevymis (Letermovir) Product Information; 2023."},{"key":"1437_CR6","unstructured":"Euroepena Medicines Agency. Prevymis (Letermovir) Summary of Product Characteristics; 2023."},{"key":"1437_CR7","unstructured":"European Medicines Agency. Livtencity (Maribavir) Summary of Product Characteristics; 2023."},{"issue":"3","key":"1437_CR8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/psp4.12593","volume":"10","author":"M Prohn","year":"2021","unstructured":"Prohn M, Viberg A, Zhang D, Dykstra K, Davis C, Macha S, et al. Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients. CPT Pharmacometr Syst Pharmacol. 2021;10(3):255\u201367.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"10","key":"1437_CR9","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2174\/18755453MTE05NDYa1","volume":"22","author":"K Menzel","year":"2021","unstructured":"Menzel K, Kothare P, McCrea JB, Chu X, Kropeit D. Absorption, metabolism, distribution, and excretion of letermovir. Curr Drug Metab. 2021;22(10):784\u201394.","journal-title":"Curr Drug Metab"},{"issue":"10","key":"1437_CR10","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/jcph.1423","volume":"59","author":"JB McCrea","year":"2019","unstructured":"McCrea JB, Macha S, Adedoyin A, Marshall W, Menzel K, Cho CR, et al. Pharmacokinetic drug\u2013drug interactions between letermovir and the immunosuppressants cyclosporine, tacrolimus, sirolimus, and mycophenolate mofetil. J Clin Pharmacol. 2019;59(10):1331\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1437_CR11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/cpdd.388","volume":"7","author":"D Kropeit","year":"2018","unstructured":"Kropeit D, von Richter O, Stobernack HP, Rubsamen-Schaeff H, Zimmermann H. Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects. Clin Pharmacol Drug Dev. 2018;7(1):9\u201321.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"1437_CR12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/cpdd.669","volume":"8","author":"YM Guo","year":"2019","unstructured":"Guo YM, Abumiya M, Yamashita T, Ubukawa K, Takahashi N. Pharmacokinetics of tacrolimus coadministered with letermovir in allogeneic hematopoietic stem cell transplantation patients. Clin Pharmacol Drug Dev. 2019;8(3):411\u20132.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"1437_CR13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.7150\/ijms.42011","volume":"17","author":"S Hikasa","year":"2020","unstructured":"Hikasa S, Shimabukuro S, Osugi Y, Ikegame K, Kaida K, Fukunaga K, et al. Tacrolimus concentration after letermovir initiation in hematopoietic stem cell transplantation recipients receiving voriconazole: a retrospective, observational study. Int J Med Sci. 2020;17(7):859\u201364.","journal-title":"Int J Med Sci"},{"issue":"8","key":"1437_CR14","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41409-020-0785-9","volume":"55","author":"KT Maples","year":"2020","unstructured":"Maples KT, Maloy M, Devlin S, Lin A, DeRespiris L, Griffin M, et al. Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipients. Bone Marrow Transpl. 2020;55(8):1687\u20139.","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"1437_CR15","first-page":"371e1-e4","volume":"28","author":"KA Marciano","year":"2022","unstructured":"Marciano KA, Seago K, Dillaman M, Ross KG, Veltri L, Cumpston A. Evaluation of the pharmacokinetic interaction between letermovir and tacrolimus in allogeneic hematopoietic cell transplantation recipients. Transplant Cell Ther. 2022;28(7):371e1-e4.","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"1437_CR16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12185-021-03277-6","volume":"115","author":"T Nakashima","year":"2022","unstructured":"Nakashima T, Inamoto Y, Aoki J, Ito A, Tanaka T, Kim SW, et al. Differences in kinetics of tacrolimus concentration after letermovir discontinuation by type of concomitant azole antifungal. Int J Hematol. 2022;115(2):158\u201362.","journal-title":"Int J Hematol"},{"issue":"4","key":"1437_CR17","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1120","volume":"11","author":"Y Shinogi","year":"2023","unstructured":"Shinogi Y, Hirai T, Ishibashi M, Ino K, Tawara I, Iwamoto T. Drug interactions of tacrolimus with letermovir and azole antifungals following hematopoietic stem cell transplantation: a retrospective observational analysis. Pharmacol Res Perspect. 2023;11(4): e01120.","journal-title":"Pharmacol Res Perspect"},{"issue":"5","key":"1437_CR18","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/jcph.2385","volume":"64","author":"G Chen","year":"2024","unstructured":"Chen G, Sun K, Michon I, Barter Z, Neuhoff S, Ghosh L, et al. Physiologically based pharmacokinetic modeling for maribavir to inform dosing in drug\u2013drug interaction scenarios with CYP3A4 inducers and inhibitors. J Clin Pharmacol. 2024;64(5):590\u2013600.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1437_CR19","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cts.13509","volume":"16","author":"K Menzel","year":"2023","unstructured":"Menzel K, Kuo Y, Chen D, Hartmann G, Wang YH, Cho CR, et al. Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological-based pharmacokinetic modeling. Clin Transl Sci. 2023;16(6):1039\u201348.","journal-title":"Clin Transl Sci"},{"issue":"7","key":"1437_CR20","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/jcph.1094","volume":"58","author":"WL Marshall","year":"2018","unstructured":"Marshall WL, McCrea JB, Macha S, Menzel K, Liu F, van Schanke A, et al. Pharmacokinetics and tolerability of letermovir coadministered with azole antifungals (posaconazole or voriconazole) in healthy subjects. J Clin Pharmacol. 2018;58(7):897\u2013904.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1437_CR21","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jac\/dkz499","volume":"75","author":"A Duong","year":"2020","unstructured":"Duong A, Sweet A, Jain R, Hill JA, Pergam SA, Boeckh M, Liu C. Clinically significant drug interaction: letermovir and voriconazole. J Antimicrob Chemother. 2020;75(3):775\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"1437_CR22","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41409-020-01093-w","volume":"56","author":"S Hikasa","year":"2021","unstructured":"Hikasa S, Shimabukuro S, Osugi Y, Ikegame K, Kaida K, Fukunaga K, et al. Decrease in voriconazole concentration-to-dose ratio after letermovir initiation: a retrospective, observational study. Bone Marrow Transplant. 2021;56(4):949\u201351.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"1437_CR23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40268-021-00365-0","volume":"21","author":"K Suetsugu","year":"2021","unstructured":"Suetsugu K, Muraki S, Fukumoto J, Matsukane R, Mori Y, Hirota T, et al. Effects of letermovir and\/or methylprednisolone coadministration on voriconazole pharmacokinetics in hematopoietic stem cell transplantation: a population pharmacokinetic study. Drugs R D. 2021;21(4):419\u201329.","journal-title":"Drugs R D"},{"issue":"6","key":"1437_CR24","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s12185-021-03105-x","volume":"113","author":"T Nakashima","year":"2021","unstructured":"Nakashima T, Inamoto Y, Fukushi Y, Doke Y, Hashimoto H, Fukuda T, Yamaguchi M. Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation. Int J Hematol. 2021;113(6):872\u20136.","journal-title":"Int J Hematol"},{"issue":"8","key":"1437_CR25","first-page":"511e1-e10","volume":"28","author":"J Lindsay","year":"2022","unstructured":"Lindsay J, Krantz EM, Morris J, Sweet A, Tverdek F, Joshi A, et al. Voriconazole in hematopoietic stem cell transplantation and cellular therapies: real-world usage and therapeutic level attainment at a major transplantation center. Transplant Cell Ther. 2022;28(8):511e1-e10.","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"1437_CR26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/cpdd.852","volume":"10","author":"A Adedoyin","year":"2021","unstructured":"Adedoyin A, Fancourt C, Menzel K, Zhao T, Tomek C, Panebianco D, et al. Assessment of pharmacokinetic interaction between letermovir and fluconazole in healthy participants. Clin Pharmacol Drug Dev. 2021;10(2):198\u2013206.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"1437_CR27","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1111\/bcp.15677","volume":"89","author":"JB McCrea","year":"2023","unstructured":"McCrea JB, Menzel K, Fancourt C, Witter R, Zhao T, Robbins JA, et al. Evaluation of the inhibitory effects of itraconazole on letermovir. Br J Clin Pharmacol. 2023;89(7):2122\u201330.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1437_CR28","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cpt.2510","volume":"111","author":"JA Robbins","year":"2022","unstructured":"Robbins JA, Menzel K, Lassman M, Zhao T, Fancourt C, Chu X, et al. Acute and chronic effects of rifampin on letermovir suggest transporter inhibition and induction contribute to letermovir pharmacokinetics. Clin Pharmacol Ther. 2022;111(3):664\u201375.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1437_CR29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/cpt.1120","volume":"105","author":"YH Wang","year":"2019","unstructured":"Wang YH, Chen D, Hartmann G, Cho CR, Menzel K. PBPK modeling strategy for predicting complex drug interactions of letermovir as a perpetrator in support of product labeling. Clin Pharmacol Ther. 2019;105(2):515\u201323.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1437_CR30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/cpdd.1043","volume":"11","author":"J Scheuenpflug","year":"2022","unstructured":"Scheuenpflug J, Kropeit D, Erb-Zohar K, Theis JGW, Stobernack HP, McCormick D, et al. The effect of oral letermovir administration on the pharmacokinetics of a single oral dose of P-glycoprotein substrate digoxin in healthy volunteers. Clin Pharmacol Drug Dev. 2022;11(1):6\u201315.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"1437_CR31","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cpdd.1071","volume":"11","author":"JB McCrea","year":"2022","unstructured":"McCrea JB, Menzel K, Adedoyin A, Cho CR, Fox-Bosetti S, Macha S, et al. Drug\u2013drug interaction of letermovir and atorvastatin in healthy participants. Clin Pharmacol Drug Dev. 2022;11(4):420\u20138.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"1437_CR32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/cpdd.1027","volume":"11","author":"D Kropeit","year":"2022","unstructured":"Kropeit D, McCormick D, Erb-Zohar K, Stobernack HP, Zimmermann H, Rubsamen-Schaeff H. Pharmacokinetics and safety of letermovir and midazolam coadministration in healthy subjects. Clin Pharmacol Drug Dev. 2022;11(1):16\u201324.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"9","key":"1437_CR33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.5414\/CP203483","volume":"57","author":"A Adedoyin","year":"2019","unstructured":"Adedoyin A, Cho CR, Fox-Bosetti S, Macha S, Zhao T, Liu F, et al. Effect of letermovir on levonorgestrel and ethinyl estradiol pharmacokinetics. Int J Clin Pharmacol Ther. 2019;57(9):450\u20137.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"1437_CR34","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/bcp.15648","volume":"89","author":"K Menzel","year":"2023","unstructured":"Menzel K, McCrea JB, Fancourt C, Witter R, Zhao T, Stoch SA, Iwamoto M. A drug\u2013drug interaction study with letermovir and acyclovir in healthy participants. Br J Clin Pharmacol. 2023;89(5):1690\u20134.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1437_CR35","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1128\/AAC.47.4.1334-1342.2003","volume":"47","author":"LH Wang","year":"2003","unstructured":"Wang LH, Peck RW, Yin Y, Allanson J, Wiggs R, Wire MB. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2003;47(4):1334\u201342.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1437_CR36","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1128\/AAC.50.4.1130-1135.2006","volume":"50","author":"JD Ma","year":"2006","unstructured":"Ma JD, Nafziger AN, Villano SA, Gaedigk A, Bertino JS Jr. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother. 2006;50(4):1130\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1437_CR37","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/jcph.1504","volume":"60","author":"IH Song","year":"2020","unstructured":"Song IH, Ilic K, Murphy J, Lasseter K, Martin P. Effects of maribavir on P-glycoprotein and CYP2D6 in healthy volunteers. J Clin Pharmacol. 2020;60(1):96\u2013106.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"1437_CR38","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/j.1600-6143.2009.02768.x","volume":"9","author":"MD Pescovitz","year":"2009","unstructured":"Pescovitz MD, Bloom R, Pirsch J, Johnson J, Gelone S, Villano SA. A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. Am J Transpl. 2009;9(10):2324\u201330.","journal-title":"Am J Transpl"},{"issue":"4","key":"1437_CR39","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13869","volume":"24","author":"DC Sabatino","year":"2022","unstructured":"Sabatino DC, Hedvat J, Salerno DM, Lange NW. Maribavir does not significantly influence tacrolimus dose requirements in solid organ transplant recipients. Transpl Infect Dis. 2022;24(4): e13869.","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"1437_CR40","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/TP.0000000000000275","volume":"98","author":"MC Verdier","year":"2014","unstructured":"Verdier MC, Patrat-Delon S, Lemaitre F, Revest M, Rivalan J, Michelet C, Bellissant E. Suspicion of interaction between maribavir and everolimus in a renal transplant recipient. Transplantation. 2014;98(3):e20\u20131.","journal-title":"Transplantation"},{"issue":"6","key":"1437_CR41","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1399-3062.2010.00550.x","volume":"12","author":"RK Avery","year":"2010","unstructured":"Avery RK, Marty FM, Strasfeld L, Lee I, Arrieta A, Chou S, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis. 2010;12(6):489\u201396.","journal-title":"Transpl Infect Dis"},{"issue":"5","key":"1437_CR42","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1128\/AAC.00951-07","volume":"52","author":"DR Goldwater","year":"2008","unstructured":"Goldwater DR, Dougherty C, Schumacher M, Villano SA. Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults. Antimicrob Agents Chemother. 2008;52(5):1794\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1437_CR43","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/cpdd.1406","volume":"13","author":"K Sun","year":"2024","unstructured":"Sun K, Ilic K, Xu P, Ye R, Wu J, Song IH. Effect of food, crushing of tablets, and antacid coadministration on maribavir pharmacokinetics in healthy adult participants: results from 2 phase 1, open-label, randomized, crossover studies. Clin Pharmacol Drug Dev. 2024;13(6):644\u201354.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1437_CR44","unstructured":"Food & Drug Adminsitration. Livtencity (Maribavir) Product Information. 2023."},{"issue":"2","key":"1437_CR45","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14267","volume":"26","author":"KJ Goodlet","year":"2024","unstructured":"Goodlet KJ, Garcia R. Effect of letermovir initiation on tacrolimus concentrations among lung transplant recipients receiving concomitant azole antifungal prophylaxis. Transpl Infect Dis. 2024;26(2): e14267.","journal-title":"Transpl Infect Dis"},{"issue":"11","key":"1437_CR46","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/jcph.2316","volume":"63","author":"DM Burger","year":"2023","unstructured":"Burger DM, le Comte M, Smolders EJ, Jacobs TG, Ter Heine R, Knibbe CAJ, Pirmohamed M. What the product label does not tell you about drug\u2013drug interaction management: time for a re-appraisal. J Clin Pharmacol. 2023;63(11):1181\u20135.","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01437-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01437-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01437-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T16:07:15Z","timestamp":1731946035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01437-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1437"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01437-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"8 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for this publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"D.M.B. is co-founder of Global DDI Solutions and received unrestricted research grants from Gilead, ViiV HealthCare, Pfizer and Merck. All payments were invoiced by the Radboudumc and paid to Radboudumc. J.M. has received research support from Pfizer and Gilead and has served as a consultant or speaker for Gilead, Pfizer, MSD, Cidara, Mundipharma, F2G, Amplyx, Basilea, Shionoghi, Synexis and Takeda. L.H. declares no interest with regards to this work. Outside of this work, he has served as consultant to and has received unrestricted research grants from Astellas Pharma, Chiesi, and Sandoz. All payments were invoiced by the Radboudumc and paid to Radboudumc. R.J.M.B. declares no interest with regards to this work. Outside of this work, he has served as consultant to and has received unrestricted research grants from Astellas Pharma Inc., F2G, Gilead sciences, Merck Sharpe and Dohme Corp., Cidara, Mundipharma Inc. and Pfizer Inc. All payments were invoiced by the Radboudumc and paid to Radboudumc. L.N., M.G., N.B., P.L. and M.C.B. have not declared a conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"DB performed the initial selection of papers, which were double checked by MG and LN. All authors reviewed draft versions of the paper and the tables, and all authors approved the final version of the paper.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}